SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq:AFFX) announced today that its GeneChip® technology will form the foundation of the new molecular cytogenetic service offering by Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH). LabCorp, an industry leader in molecular diagnostic testing, is making the service available to customers across the United States.
